Liquid Biopsy in Mature B-cell Tumors
ConditionMature B-Cell Neoplasm
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorOncology Institute of Southern Switzerland
About this trial
The study aims at assessing whether cell free DNA genotyping can improve the accuracy of early prediction of cure in mature B-cell tumor patients and whether it represents an accessible source of tumor DNA for the sensitive identification of genetic biomarkers that refine the diagnostic workup, stratify prognosis and identify the emergence of drug-resistance mutations during treatment.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Male or female adults 18 years or older
Documented diagnosis of mature B-cell tumor according to WHO 2008 criteria
Willing and able to comply with scheduled study procedures
Evidence of a signed informed consent
Disqualifiers
None
Trial population
Male or female adults 18 years or older with a documented diagnosis of mature B-cell tumor according to WHO 2008 criteria
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Liquid Biopsy
Diagnostic testAssessing whether plasma cell free DNA improves the accuracy of early prediction of cure in mature B-cell tumor patients and whether it represents an accessible source of tumor DNA for the sensitive identification of genetic biomarkers that, at disease presentation, refine the diagnostic workup in mature B-cell tumor patients and, upon treatment, early identify the emergence of resistance mutations.
Treatment groups
No treatment groups listed
Trial outcomes
Primary outcomes
1
Accuracy of interim plasma cell free DNA genotyping for cHL patients
Assessment of interim plasma cell free DNA genotyping accuracy in the identification of cured vs non cured patients in cHL (patients not progressed after 24 months)
Time frame
24 months from treatment2
Accuracy of interim plasma cell free DNA genotyping for DLBCL patients
Assessment of interim plasma cell free DNA genotyping accuracy in the identification of cured vs non cured patients in DLBCL (patients not progressed after 24 months)
Time frame
24 months from treatment3
Accuracy of interim plasma cell free DNA genotyping for FL patients
Assessment of interim plasma cell free DNA genotyping accuracy in the identification of patients in continuous complete remission at 24 months from first line treatment vs patients not in continuous complete remission at 24 months from first line treatment in FL and other indolent B-cell lymphoproliferative disorders
Time frame
24 months from treatment4
Accuracy of interim plasma cell free DNA genotyping for MCL patients
Assessment of interim plasma cell free DNA genotyping accuracy in the identification of patients in continuous complete remission at 24 months from first line treatment vs patients not in continuous complete remission at 24 months from first line treatment in MCL
Time frame
24 months from treatmentSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov